MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy Interventions: Biological: NTLA-2001; Drug: Placebo Sponsors: Intellia Therapeutics; Regeneron Pharmaceuticals Not yet recruiting

https://clinicaltrials.gov/study/NCT06128629

Source: ClinicalTrials.gov - November 13, 2023 Category: Research Source Type: clinical trials